bpc-157 human clinical trials safety fda status FDA's Review Of Peptides Signals A Growing Public Health Challenge FDA commitee votes 8-6 to

The most commonly reported side effects are mild and transient, including injection site reactions (redness, slight swelling, or tenderness), mild headaches during the initial days of use, and occasional dizziness or lightheadedness, particularly when starting the peptide

Some researchers prefer to add more water (3-5 mL) to create a more dilute solution that requires a larger, easier-to-measure draw

Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters

I don't need you to keep repeating so condescendingly - AS I've already said - I know that IM releases more slowly

Human Research Findings The majority of current data on BPC-157 originates from animal studies, demonstrating consistent advantages in tissue healing, angiogenesis, and inflammatory regulation [1][4]